Posted by Michael Wonder on 12 Aug 2022
Enhertu approved in the U.S. as the first HER2 directed therapy for patients with previously treated HER2 mutant metastatic non-small-cell lung cancer
12 August 2022 - Based on DESTINY-Lung02 results which showed Daiichi Sankyo and AstraZeneca’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2 mutant disease.
Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumours have activating HER2 (ERBB2) mutations, as detected by an FDA approved test, and who have received a prior systemic therapy.
